Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 291

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993

Open access
Fielding, Adele K., Rowe, Jacob M., Richards, Susan M., Buck, Georgina, Moorman, Anthony V., Durrant, I. Jill, Marks, David I., McMillan, Andrew K., Litzow, Mark R., Lazarus, Hillard M., Foroni, Letizia, Dewald, Gordon, Franklin, Ian M., Luger, Selina M., Paietta, Elisabeth, Wiernik, Peter H., Tallman, Martin S., Goldstone, Anthony H.·2009·Blood

Abstract

Prospective data on the value of allogeneic hematopoietic stem cell transplantation (alloHSCT) in Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) are limited. The UKALLXII/ECOG 2993 study evaluated the outcome of assigning alloHSCT with a sibling (sib) or matched unrelated donor (MUD) to patients younger than 55 years of age achieving complete remission (CR). The CR rate of 267 patients, median age 40, was 82%. Twenty-eight percent of patients proceeded to alloHSCT in first CR. Age older than 55 years or a pre-HSCT event were the most common reasons for failure to progress to alloHSCT. At 5 years, overall survival (OS) was 44% after sib alloHSCT, 36% after MUD alloHSCT, and 19% after chemotherapy. After adjustment for sex, age, and white blood count and excluding chemotherapy-treated patients who relapsed or died before the median time to alloHSCT, only relapse-free survival remained significantly superior in the alloHSCT group (odds ratio 0.31, 95% confidence interval 0.16-0.61). An intention-to-treat analysis, using the availability or not of a matched sibling donor, showed 5-year OS to be nonsignificantly better at 34% with a donor versus 25% with no donor. This prospective trial in adult Ph+ ALL indicates a modest but significant benefit to alloHSCT. This trial has been registered with clinicaltrials.gov under identifier NCT00002514 and as ISRCTN77346223.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-01-199380

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 291

Metadata

Authors
Fielding, A. K., Rowe, J. M., Richards, S. M., Buck, G., Moorman, A. V., Durrant, I. J., Marks, D. I., McMillan, A. K., Litzow, M. R., Lazarus, H. M., Foroni, L., Dewald, G., Franklin, I. M., Luger, S. M., Paietta, E., Wiernik, P. H., Tallman, M. S., & Goldstone, A. H.
Venue
Blood
Published
2009-05-07
Volume
113
Issue
19
Pages
4489-4496
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2037148599
Cited by
291
References
17
FWCI
22.54
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. https://app.cochat.ai/papers/10.1182/blood-2009-01-199380
The paper
Fielding, A. K., Rowe, J. M., Richards, S. M., Buck, G., Moorman, A. V., Durrant, I. J., Marks, D. I., McMillan, A. K., Litzow, M. R., Lazarus, H. M., Foroni, L., Dewald, G., Franklin, I. M., Luger, S. M., Paietta, E., Wiernik, P. H., Tallman, M. S., & Goldstone, A. H. (2009). Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. https://doi.org/10.1182/blood-2009-01-199380

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.